BRD3: A Non-Coding RNA Molecule with Multiple Functions in Cellular Regulation

Target Name: BRD3

NCBI ID: G8019

BRD3

BRD3: A Non-Coding RNA Molecule with Multiple Functions in Cellular Regulation

BRD3 (Bromodomain-containing 3), also known as HDAC11, is a non-coding RNA molecule that plays a crucial role in gene regulation and DNA replication. Discovered in 2004, BRD3 has since been shown to be involved in numerous cellular processes, including DNA repair, cell growth, and cell survival. Its unique structure, which consists of a domain that contains a bromodomain and a hydrophobic tail, has led to a high degree of interest in both basic and disease-related research.

BRD3 functions as a negative regulator of the chromatin-remodeling enzyme, HDAC11. This protein works by binding to specific DNA sequences and preventing the recruitment of other enzymes to the site. By doing so, it helps to maintain the integrity of the chromatin structure and ensures that gene expression is regulated.

BRD3 has been shown to play a key role in a variety of biological processes, including cancer, cell growth, and aging. For example, high levels of BRD3 have been associated with an increased risk of certain types of cancer, such as breast, ovarian, and prostate cancer. Additionally,BRD3 has been linked to various cellular processes that are associated with aging, including the regulation of cellular senescence, the DNA damage response, and the regulation of cellular apoptosis.

BRD3 is also a potential drug target in the pharmaceutical industry. Its unique structure and the various functions it is associated with have made it an attractive target for small molecules and other therapeutic agents. Several compounds have already been shown to interact with BRD3 and have the potential to be used in cancer and other diseases.

One of the compounds that has shown promise in targeting BRD3 is called S1825, which is a small molecule inhibitor of HDAC11. In preclinical studies, S1825 has been shown to decrease the levels of BRD3 in cancer cells and inhibit its functions. Further testing is ongoing to determine if S1825 is safe and effective as a cancer treatment.

Another compound that has shown potential in targeting BRD3 is called NEDD8, which is a small molecule inhibitor of HDAC11. In preclinical studies, NEDD8 has been shown to decrease the levels of BRD3 in cancer cells and inhibit its functions. Further testing is ongoing to determine if NEDD8 is safe and effective as a cancer treatment.

BRD3 is also a potential biomarker for several diseases, including cancer. Its levels have been shown to be elevated in a variety of cancer types, including breast, ovarian, and prostate cancer. Additionally, its functions have been implicated in the regulation of cellular processes that are associated with cancer, such as cell growth, apoptosis, and angiogenesis.

BRD3 has also been shown to play a role in the regulation of cellular senescence, a process that is associated with the aging process. This protein has been shown to interact with several transcription factors, including p21, and play a role in the regulation of cellular senescence.

In conclusion, BRD3 is a non-coding RNA molecule that has been shown to play a crucial role in a variety of cellular processes, including gene regulation, DNA replication, and cell survival. Its unique structure, which consists of a domain that contains a bromodomain and a hydrophobic tail, has led to a high degree of interest in both basic and disease-related research. Additionally, its functions have been implicated in a variety of diseases, including cancer, cell growth, and aging. As a potential drug target and biomarker, BRD3 is an attractive target for small molecules and other therapeutic agents. Further research is needed to fully understand its role in these processes and to determine its potential as a therapeutic agent.

Protein Name: Bromodomain Containing 3

Functions: Chromatin reader that recognizes and binds hyperacetylated chromatin and plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors (PubMed:18406326, PubMed:27105114). Regulates transcription by promoting the binding of the transcription factor GATA1 to its targets (By similarity)

The "BRD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BRD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets